Hikma Is Prepared For Tougher Pricing Environment In 2022
CEO Siggi Olafsson Outlines Investment Priorities And Offers Key Product Updates
Hikma is prepared for additional competitors on key products as well as growing price pressure in the US, CEO Siggi Olafsson tells Generics Bulletin in the second part of an exclusive interview.
You may also be interested in...
Hikma And Glenmark Launch Ryaltris In US
Hikma and Glenmark have announced the long-awaited launch of the Ryaltris nasal spray on which the two companies have partnered in the US.
Hikma Eyes Return To Growth After Further Cutting Generics Forecasts
Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.
Glenmark Builds US OTC Lineup In Wockhardt Deal
Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.